Full text - PDF - The National Cancer Institute

More documents

Recommendations

Info

300Cyclin A and Cyclin D1 as Significant Prognostic Markersbetween patients with and without overexpressionof Ki-67.In conclusion, our results demonstrate thatcyclin D1, cyclin A, histone H3 and Ki-67 areoverexpressed in a subset of CRC cases. Overexpressionof both cyclin D1 and cyclin A correlateswith poor differentiation and tumor progression.Our results also indicate the superiorityof cylcin A and cyclin D1 as indicators of poorprognosis compared to Ki-67 and histone H3mRNA in colorectal carcinoma. Overexpressionof cyclin A and D1 is thus identified as a significant,independent prognostic factor for colorectalcarcinoma. Our findings in this regard are especiallyimportant in stage I and II patients sincethose patients usually have a poor prognosis inspite of being node-negative. Hence, in thisgroup of patients there is a great demand formore accurate, individually-based, biologicalprognostic factors that help in accurate predictionof the clinical outcome of the disease as well asin categorizing patients for appropriate therapeuticmodalities. If these findings are confirmedin a larger study, evaluation of cyclin A and D1may be applicable to clinical management ofCRC, allowing the identification of patients withpoor prognosis. It will also be valuable to comparethe prognostic impact of these two parametersin two separate groups including metastaticand non-metastatic CRC.REFERENCES1- Arber N., Hibshoosh,H., Moss S., Sutter T., Zhang Y.,Begg M., Wang S., Weinstein I. and Holt P.: Increasedexpression of cyclin D1 is an early event in multistagecolorectal carcinogenesis. Gastroenterol., 110: 669-674, 1996.2- Bartkova J., Lukas J., Strauss, M., and Bartek J.: ThePRAD-1/cyclin D1 oncogene product accumulatesaberrantly in a subset of colorectal carcinomas. Int J.Cancer, 58: 568-573, 1994.3- Buckley M., Sweeney K., Hamilton J., Sini R., ManningD., Nicholson R., DeFazio A., watts C., Musgrove E.,and Sutherland R.: Expression and amplification ofcyclin genes in human breast cancer. Oncogene, 8:2127-2133, 1993.4- Chao Y., Shih Y., Chiu J., Chau G., Lui W., Yang W.,Lee S. and Huang T.: Overexpression of cyclin A butnot SKP 2 correlates with the tumor relapse of humanhepatocellular carcinoma. Cancer Res., 58: 985-990.1998.5- Chou M., Chang A., McBride J., Donoff B., GallagherG. and Wong D. A.: Rapid method to determine proliferationpatterns of normal and malignant tissues byH3 mRNA in situ hybridization. Am. J. Pathol., 136:729-733. 1990.6- Cordon-Cardo C.: Mutations of cell cycle regulators.Biological and clinical implications for human neoplasia.Am.r J. Pathol., 147: 545-560, 1995.7- Gerdes J., Lemke H., Baisch H., Wacker H., SchwabU., and Stein H.: Cell cycle analysis of a cell proliferation-associatedhuman nuclear antigen defined by themonoclonal antibody Ki-67. Immunol., 133: 1710-1715. 1984.8- Gillett C., Fantl V., Smith R., Fisher C., Bartek J.,Dickson C., Barnes D., and Peters G. Amplificationand overexpression of cyclin D1 in breast cancerdetected by immunohistochemical staining. CancerRes., 54: 1812-1817, 1994.9- Girard F., Strausfield U., Fernandez A. and Lamb N.:Cyclin A is required for the onset of DNA replicationin mammalian fibroblasts. Cell, 67: 1169-1179, 1991.10- Gown A., Jiang J., Matles H., Skelly M., GoodpasterT., Cass L., Reshatof M., Spaulding D. and ColtreraM.: Validation of the S-phase specificity of histone(H3) in situ hybridization in normal and malignantcells. J. Histochem Cytochem., 44: 221-226, 1996.11- Handa K., Yamakaua M., Takeda H., Kimura S. andTakahashi T.: Expression of the cell cycle markers incolorectal carcinoma: Superiority of cyclin A as anindicator of poor prognosis. Int J. Cancer, 84: 225-233, 1999.12- Hebermann J., Lenander C., Roblick U.J., Kruger S.,Ludwig D., Alaiya A., Freitag S., Dumbgen L., BruchHP., Stange E., Salo S., Tryggvason K., Auer G. andSchimmelpenning H.: Ulcerative colitis and colorectalcarcinoma: DNA profile, laminin-5 gamma 2 chainand cyclin A expression as early markers for riskassessment. Scand J. Gastroenterol., 36 (7): 751-758,2001.13- Holland T., Elder J., McCloud J., Hall C., Deakin M.,Fryer A., Elder G. and Hoban P.: Subcellular localizationof cyclin D1 protein in colorectal tumors is associatedwith p21 (WAF1/CIP1) expression and correlateswith patient survival. Int J. Cancer, 95 (5): 302-306,2001.14- Hunter T. and Pines J.: Cyclins and cancer. II. CyclinD and CDK inhibitors come of age. Cell, 79: 573-5781994.15- Jares P., Fernandez P., Campo E., Nadal A., BoschoF., Aiza G., Nayach I., Traserra J. and Cardesa A.:PRAD-1/cyclin D1 gene amplification correlates withmessenger RNA overexpression and tumor progressionin human laryngeal carcinomas. Cancer Res., 54: 4813-4817, 1994.16- Jass J. and Sobin L.H.: World Health Organization.International classification of tumors: histologicaltyping of intestinal tumors, Springer, New York., 1989.17- Jiang G-L. and Huang S.: Adenovirus expressing RIZ1in tumor suppressor gene therapy of microsatelliteunstable colorectal cancers. Cancer Res., 61:1796-1798, 2001.
Abeer A. Bahnassy, et al. 30118- King R., Coffer A., Gilbert J., Lewis K., Nash R., MillisR., Raju S. and Taylor R.: Histochemical studies witha monoclonal antibody raised against a partially purifiedsoluble estradiol receptor preparation from humanmyometrium. Cancer Res., 45: 5728-5733, 1985.19- Kubota Y., Petras R., Easley K., Bauer T., Tubbe R.and Fazio V.: Ki-67-determined growth fraction versusstandard staging and grading parameters in colorectalcarcinoma. A multivariate analysis. Cancer, 70: 2602-2609, 1992.20- Leach F., Elledge S., Willson J., Markowitz S., KinzlerK. and Vogelstein B. Amplification of cyclin genes incolorectal carcinomas. Cancer Res., 53: 1986-1989.1993.21- Maeda K., Chung Y., Kang S., Ogawa M., Onoda N.,Nakata B., Nishiguchi Y., Okuno M., and Sowa M.Overexpression of cyclin D1 and p53 is associatedwith disease recurrence in colorectal adenocarcinoma.Int J. Cancer, 74: 310-315, 1997.22- Mate J., Ariza A., Arcil C., Lopez D., Isamat M., Perez-Piteira J. and Navas- Palacios J.: Cyclin D1 overexpressionin non- small cell lung carcinoma: correlationwith Ki-67 labeling index and poor cytoplasmic differentiation.J. Pathol., 180: 395- 399, 1996.23- McKay J., Douglas J., Ross V., Curran S., Loane J.,Ahmed F., Cassidy J.,McLeod H. and Murray G.:Analysis of key cell cycle checkpoint proteins incolorectal tumors. J. Pathol., 196 (4): 386-393, 2002.24- Motokura T. and Arnold A.: Cyclins and oncogenesis.Biochim. Biophys. Acta., 1155: 63-78, 1993.25- Nagao T., Ishida Y. and Kondo Y.: Determination ofS-phase cells by in situ hybridization for histone H3mRNA in hepatocellular carcinoma: correlation withhistological grade and other cell proliferative markers.Mod Pathol., 9: 99-104, 1996.26- Pagano M., Pepperkok R., Verde F., Ansorge W. andDraetta G. Cyclin A is required at two points in thehuman cell cylce. EMBO J., 11: 961-971, 1992.27- Pasz-Walczak G., Kordek R. and faflik M.: P21 (WAF1)expression in colorectal cancer: correlation with p53and cyclin D1 expression, clinicopathological parametersand prognosis. Pathol Res Pract., 197 (10): 683-689, 2001.28- Robert J.C., Boerrigter L., Evers S.G., Wisman P.,Mooiw J. and Rodenhuis S. A rapid and simple procedurefor the routine detection of ras point mutationsin formalin-fixed, paraffin-embedded tissues. DigMolec. Path., 1 (2):136-139, 1992.29- Shain A., Ro I., Brown R., Ordonez N., Cleary K., El-Naggar A., Wilson P. and Ayala A.: Assessment of Ki-67- derived tumor proliferative activity in colorectaladenocarcinomas. Mod Pathol., 7: 17-22, 1994.30- Sobin L. and Wittekind C.: TNM classification ofmalignant tumors (5 th ed). John Wiley, New York.,1997.31- Soliman A., Bondy M., Levin B., Hamza M.R., IsmailK., Ismail S., Hammam H.M., El-Hattab O., KamalS.M., Soliman A.A., Dorgham L.A., McPherson R.S.,and Beasley P.R.: Colorectal cancer in Egyptian patientsunder 40 years of age. Int J. Cancer, 71: 26-30, 1997.32- Soliman A., Bondy M., Guan Y., El-Badawi S., MokhtarN., Bayomi S., Raouf AA., Ismail S., McPherson RS.,Abdel-Hakim TF., Beasley PR. Levin B. and Wei Q.:Reduced expression of mismatch repair genes in colorectalcancer patients in Egypt. Int J. Oncology, 12:1315-1319, 1998.33- Suzuki H., Matsumoto K. and Terabe M.: Ki-67antibody labeling index in colorectal carcinoma. J.Clin Gastroenterol., 15: 317-320, 1992.34- Utsunomiya T., Doki Y., Takemoto H., Shiozaki H.,Yano M., Sekimoto M., Tamura S., Yasuda T., FujiwaraY. and Monden M.: Correlation of beta-catenin andcyclin D1 expression in colon cancers. Oncology, 61(3): 226-233, 2001.35- Volm M., Koomagi R., Mattern J. and Stammler G.:Cyclin A in lung carcinomas. Br. J. Cancer, 75: 1774-1778, 1997.36- Wang A., Yoshimi N., Suzui M., Yamauch1 A., TaraoM. and Mori H.: Different expression patterns of cyclinsA, D1 and E in human colorectal cancer. J. CancerRes. Clin. Oncol., 122: 122-126, 1996.37- Zhuai Y.L., Nikaido T., Shiozawa T., Orii A. and FujiS.: Expression of cyclins and cyclin dependant kinasesin smooth muscle tumors of the uterus. Int J. Cancer(pred. Oncol.), 84: 244-250, 1999.
Page 1 and 2: Journal of the Egyptian Nat. Cancer
Page 3 and 4: Abeer A. Bahnassy, et al. 291(X200)
Page 5 and 6: Abeer A. Bahnassy, et al. 293Fig. (
Page 7 and 8: Abeer A. Bahnassy, et al. 295Fig. (
Page 9 and 10: Abeer A. Bahnassy, et al. 297Table
Page 11: Abeer A. Bahnassy, et al. 299cancer

Full text - PDF - The National Cancer Institute

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?